# Heart Failure - Pathway.md Article

**Source:** https://www.pathway.md/diseases/heart-failure-rectslm30dGoeF3RH

## Definition

Heart failure (HF) is "a clinical syndrome that results from structural or functional impairment of filling or ejection of blood from the heart."

### Classification by Ejection Fraction
- **HFrEF (Heart Failure with Reduced Ejection Fraction)**: ≤ 40%
- **HFpEF (Heart Failure with Preserved Ejection Fraction)**: ≥ 50%
- **HFmrEF (Heart Failure with Mid-Range Ejection Fraction)**: 41-50%

## Epidemiology

- **Incidence**: 219.3 cases per 100,000 person-years
- **Prevalence**: 1,915 persons per 100,000 population

## Causes

The most common causes of heart failure include:
1. Ischemic heart disease
2. Hypertensive heart disease
3. Valvular and rheumatic heart disease
4. Genetic cardiomyopathies
5. Congenital heart disease

## Clinical Manifestations

### 1. Pulmonary Symptoms
- Dyspnea
- Orthopnea
- Paroxysmal nocturnal dyspnea

### 2. Peripheral Symptoms
- Ankle swelling
- Abdominal bloating

### 3. Inflammatory Pathway Activation
- Early satiety
- Cachexia

### 4. Severe HF Manifestations
- Mild fatigue
- Exertional intolerance
- Cardiogenic shock

## Prognosis

- **1-year mortality**: 20.2%
- **5-year mortality**: 56.2%
- Over 50% of deaths are due to non-cardiovascular events

## Diagnostic Investigations

1. Clinical evaluation
2. Laboratory tests
3. ECG
4. Cardiopulmonary exercise testing
5. Natriuretic peptide biomarkers
6. Chest radiography
7. Echocardiography (TTE)
8. Advanced cardiac imaging
9. Lung ultrasound
10. Psychosocial assessment

## Key Management Principles

### Risk Stratification
- Use validated multivariable risk scores
- Estimate incident HF risk and mortality

### Treatment Guidelines
1. Provide multidisciplinary care
2. Implement guideline-directed medical therapy
3. Address self-care barriers
4. Reduce re-hospitalization risk
5. Improve survival

### Pharmacologic Management
- Renin-angiotensin system inhibitors
- Mineralocorticoid receptor antagonists
- Beta-blockers
- Diuretics
- SGLT-2 inhibitors

### Nonpharmacologic Interventions
- Optimize medication regimens
- Address lifestyle factors
- Consider device therapy where appropriate

## Note on Content Extraction

This is a partial extraction of the heart failure article from Pathway.md. The full article requires authentication and interactive access to expand all sections. The content above represents the information that was accessible through automated extraction.

To obtain the complete article with all references, PubMed links, DOI citations, and internal calculator links, manual access with proper authentication is required.

## References

The following PubMed references were extracted from the complete Pathway.md article:

1. [Boback Ziaeian, Gregg C Fonarow. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78.](https://pubmed.ncbi.nlm.nih.gov/26935038/)

2. [Ziaeian B, Fonarow GC, . Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78.](https://pubmed.ncbi.nlm.nih.gov/26935038)

3. [Komanduri S, Jadhao Y, Guduru SS et al. Prevalence and risk factors of heart failure in the USA: NHANES 2013 - 2014 epidemiological follow-up study. J Community Hosp Intern Med Perspect. 2017 Mar 3](https://pubmed.ncbi.nlm.nih.gov/28634519)

4. [Metra M, Teerlink JR. Heart failure. Lancet. 2017 Oct 28;390(10106):1981-1995.](https://pubmed.ncbi.nlm.nih.gov/28460827)

5. [Paul A Heidenreich, Biykem Bozkurt, David Aguilar et al. 2022 AHA / ACC / HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology / American Heart Association](https://pubmed.ncbi.nlm.nih.gov/35363499/)

6. [Theresa A McDonagh, Marco Metra, Marianna Adamo et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726.](https://pubmed.ncbi.nlm.nih.gov/34447992/)

7. [Katja Zeppenfeld, Jacob Tfelt-Hansen, Marta de Riva et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2](https://pubmed.ncbi.nlm.nih.gov/36017572/)

8. [Annemarie Thompson, Kirsten E Fleischmann, Nathaniel R Smilowitz et al. 2024 AHA / ACC / ACS / ASNC / HRS / SCA / SCCT / SCMR / SVM Guideline for Perioperative Cardiovascular Management for Noncard](https://pubmed.ncbi.nlm.nih.gov/39316661/)

9. [Theresa A McDonagh, Marco Metra, Marianna Adamo et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(](https://pubmed.ncbi.nlm.nih.gov/37622666/)

10. [Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the Europea](https://pubmed.ncbi.nlm.nih.gov/37345492/)

11. [Isabelle C Van Gelder, Michiel Rienstra, Karina V Bunting et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-T](https://pubmed.ncbi.nlm.nih.gov/39210723/)

12. [Alistair J Roddick, Alexa Wonnacott, David Webb et al. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPD](https://pubmed.ncbi.nlm.nih.gov/37880609/)

13. [Hiten Patel, Christopher Skok, Anthony DeMarco. Peripheral Edema: Evaluation and Management in Primary Care. Am Fam Physician. 2022 Nov;106(5):557-564.](https://pubmed.ncbi.nlm.nih.gov/36379502/)

14. [Nishimura RA, Otto CM, Bonow RO et al. 2017 AHA / ACC Focused Update of the 2014 AHA / ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of](https://pubmed.ncbi.nlm.nih.gov/28298458)

15. [Minoru Ono, Osamu Yamaguchi, Tomohito Ohtani et al. JCS / JSCVS / JATS / JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure. Circ J. 2022 Ma](https://pubmed.ncbi.nlm.nih.gov/35387921/)

16. [Paul K Whelton, Robert M Carey, Wilbert S Aronow et al. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH / ASPC / NMA / PCNA Guideline for the Prevention, Detection, Evaluation, and Managemen](https://pubmed.ncbi.nlm.nih.gov/29133356/)

17. [Sana M Al-Khatib, William G Stevenson, Michael J Ackerman et al. 2017 AHA / ACC / HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: ](https://pubmed.ncbi.nlm.nih.gov/29084731/)

18. [Sunil V Rao, Michelle L O'Donoghue, Marc Ruel et al. 2025 ACC / AHA / ACEP / NAEMSP / SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College ](https://pubmed.ncbi.nlm.nih.gov/40014670/)

19. [Marc Humbert, Gabor Kovacs, Marius M Hoeper et al. 2022 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731.](https://pubmed.ncbi.nlm.nih.gov/36017548/)

20. [American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Acute Heart Failure Syndromes. Clinical Policy: Critical Issues in the Evaluation and Management of A](https://pubmed.ncbi.nlm.nih.gov/36153055/)

21. [Sigrun Halvorsen, Julinda Mehilli, Salvatore Cassese et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(](https://pubmed.ncbi.nlm.nih.gov/36017553/)

22. [John William McEvoy, Cian P McCarthy, Rosa Maria Bruno et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018.](https://pubmed.ncbi.nlm.nih.gov/39210715/)

23. [W Timothy Garvey, Jeffrey I Mechanick, Elise M Brett et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR M](https://pubmed.ncbi.nlm.nih.gov/27219496/)

24. [G B John Mancini, Eileen O'Meara, Shelley Zieroth et al. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Ad](https://pubmed.ncbi.nlm.nih.gov/35961754/)

25. [Marcus GM, Gerber IL, McKeown BH et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA. 2005 May 11;293(18):2238-44.](https://pubmed.ncbi.nlm.nih.gov/15886379)

26. [Morgan S, Smith H, Simpson I et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ. 1999 Fe](https://pubmed.ncbi.nlm.nih.gov/9933201)

27. [Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul 18;347(3):161-7.](https://pubmed.ncbi.nlm.nih.gov/12124404)

28. [Wang CS, FitzGerald JM, Schulzer M et al. Does this dyspneic patient in the emergency department have congestive heart failure?. JAMA. 2005 Oct 19;294(15):1944-56.](https://pubmed.ncbi.nlm.nih.gov/16234501)

29. [Yancy CW, Jessup M, Bozkurt B et al. 2017 ACC / AHA / HFSA Focused Update of the 2013 ACCF / AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology / Ame](https://pubmed.ncbi.nlm.nih.gov/28455343)

30. [Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436-48.](https://pubmed.ncbi.nlm.nih.gov/19920054)

31. [Yancy CW, Januzzi JL Jr, Allen LA et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Eject](https://pubmed.ncbi.nlm.nih.gov/29277252)

32. [Bozkurt B, . What Is New in Heart Failure Management in 2017? Update on ACC / AHA Heart Failure Guidelines. Curr Cardiol Rep. 2018 Apr 17;20(6):39.](https://pubmed.ncbi.nlm.nih.gov/29667019)

33. [Atherton JJ, Sindone A, De Pasquale CG et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart fa](https://pubmed.ncbi.nlm.nih.gov/30067937)

34. [Simone Frea, Stefano Pidello, Alessandra Volpe et al. Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemid](https://pubmed.ncbi.nlm.nih.gov/31256261/)

35. [Eileen O'Meara, Michael McDonald, Michael Chan et al. CCS / CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis ](https://pubmed.ncbi.nlm.nih.gov/32036861/)

36. [Ali Ahmed. American College of Cardiology / American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003 Jan;5](https://pubmed.ncbi.nlm.nih.gov/12534856/)

37. [Charlene Bredy, Margherita Ministeri, Alexander Kempny et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise a](https://pubmed.ncbi.nlm.nih.gov/28950356/)

38. [Ian G Stiell, Jeffrey J Perry, Catherine M Clement et al. Prospective and Explicit Clinical Validation of the Ottawa Heart Failure Risk Scale, With and Without Use of Quantitative NT-proBNP. Acad ](https://pubmed.ncbi.nlm.nih.gov/27976497/)

39. [L Goldman, B Hashimoto, E F Cook et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation.](https://pubmed.ncbi.nlm.nih.gov/7296795/)

40. [Stefan D Anker, Javed Butler, Gerasimos Filippatos et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461.](https://pubmed.ncbi.nlm.nih.gov/34449189/)

41. [Barry M Massie, Peter E Carson, John J McMurray et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67.](https://pubmed.ncbi.nlm.nih.gov/19001508/)

42. [Justin A Ezekowitz, Eloisa Colin-Ramirez, Heather Ross et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled t](https://pubmed.ncbi.nlm.nih.gov/35381194/)

43. [Justin A Ezekowitz, Eileen O'Meara, Michael A McDonald et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017 N](https://pubmed.ncbi.nlm.nih.gov/29111106/)

44. [Milton Packer, Stefan D Anker, Javed Butler et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424.](https://pubmed.ncbi.nlm.nih.gov/32865377/)

45. [Adriaan A Voors, Christiane E Angermann, John R Teerlink et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 ](https://pubmed.ncbi.nlm.nih.gov/35228754/)

46. [Scott D Solomon, John J V McMurray, Brian Claggett et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098.](https://pubmed.ncbi.nlm.nih.gov/36027570/)

47. [Alexandre Mebazaa, Beth Davison, Ovidiu Chioncel et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multination](https://pubmed.ncbi.nlm.nih.gov/36356631/)

48. [Frederik H Verbrugge, Venu Menon. Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial. Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):931-932.](https://pubmed.ncbi.nlm.nih.gov/36351030/)

49. [Julio Núñez, Pau Llàcer, Vicente Bertomeu-González et al. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study. JACC Heart Fail. 2016 Nov;4(11):833-843. ](https://pubmed.ncbi.nlm.nih.gov/27522630/)

50. [Bram Rochwerg, Laurent Brochard, Mark W Elliott et al. Official ERS / ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017 Aug 31;50(2). pii:](https://pubmed.ncbi.nlm.nih.gov/28860265/)

51. [Markovic Domagoj, Jurcevic Zidar Branka, Macanovic Jelena et al. Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart fai](https://pubmed.ncbi.nlm.nih.gov/29678315/)

52. [Robert David Jarman, Cian McDermott, Anna Colclough et al. EFSUMB Clinical Practice Guidelines for Point-of-Care Ultrasound: Part One (Common Heart and Pulmonary Applications) LONG VERSION. Ultras](https://pubmed.ncbi.nlm.nih.gov/36228631/)

53. [Scott D Solomon, John J V McMurray, Inder S Anand et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609-1620.](https://pubmed.ncbi.nlm.nih.gov/31475794/)

54. [Eric J Velazquez, David A Morrow, Adam D DeVore et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548.](https://pubmed.ncbi.nlm.nih.gov/30415601/)

55. [Mikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084](https://pubmed.ncbi.nlm.nih.gov/37622681/)

56. [Mandeep R Mehra, Ivan Netuka, Nir Uriel et al. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. ](https://pubmed.ncbi.nlm.nih.gov/37950897/)

57. [Joel M Neutel, David H G Smith, Michael A Weber. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004 Jan;17(1)](https://pubmed.ncbi.nlm.nih.gov/14700510/)

58. [H T Colfer, H S Ribner, A Gradman et al. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study G](https://pubmed.ncbi.nlm.nih.gov/1632402/)

59. [Gad Cotter, Benjamin Deniau, Beth Davison et al. Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized C](https://pubmed.ncbi.nlm.nih.gov/38150260/)

60. [Waguih William IsHak, Michele A Hamilton, Samuel Korouri et al. Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Net](https://pubmed.ncbi.nlm.nih.gov/38231511/)

61. [Paul R Kalra, John G F Cleland, Mark C Petrie et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective](https://pubmed.ncbi.nlm.nih.gov/36347265/)

62. [Orly Vardeny, Akshay S Desai, Pardeep S Jhund et al. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. JAMA Cardiol. 2024 ](https://pubmed.ncbi.nlm.nih.gov/38265835/)

63. [Alexander T Sandhu, Jamie Calma, Megan Skye et al. Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic. Circulation. 2024 May 28;149(22):1717-1728.](https://pubmed.ncbi.nlm.nih.gov/38583147/)

64. [Vaduganathan M, Claggett BL, Desai AS et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril / Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 202](https://pubmed.ncbi.nlm.nih.gov/31726194/)

65. [John J V McMurray, Scott D Solomon, Silvio E Inzucchi et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.](https://pubmed.ncbi.nlm.nih.gov/31535829/)

66. [Jelle P Man, Maarten A C Koole, Paola G Meregalli et al. Digital consults in heart failure care: a randomized controlled trial. Nat Med. 2024 Oct;30(10):2907-2913.](https://pubmed.ncbi.nlm.nih.gov/39217271/)

67. [Stefan D Anker, Tim Friede, Ralph-Stephan von Bardeleben et al. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med. 2024 Nov 14;391(19):1799-180](https://pubmed.ncbi.nlm.nih.gov/39216092/)

68. [Nuccia Morici, Alice Sacco, Simone Frea et al. Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial. J Am Coll Cardiol. 2025 Apr 29;85(16):15](https://pubmed.ncbi.nlm.nih.gov/40162941/)

69. [Stefan D Anker, Tim Friede, Javed Butler et al. Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA. 2025 Mar 30. Online ah](https://pubmed.ncbi.nlm.nih.gov/40159390/)

70. [Maria A Pabon, Orly Vardeny, Muthiah Vaduganathan et al. Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025 May 21:e251101. ](https://pubmed.ncbi.nlm.nih.gov/40397470/)

71. [Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson et al. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 202](https://pubmed.ncbi.nlm.nih.gov/40531488/)

## Related Heart Failure Calculators

The following calculators from Pathway.md are relevant to heart failure assessment and management:

- [Assessment of diastolic function (no LV structural pathology)](https://www.pathway.md/calculators/assessment-of-diastolic-function-no-lv-structural-pathology-rec4NZLGrCSw7xOjL)
- [NYHA functional classification for heart failure](https://www.pathway.md/calculators/nyha-functional-classification-for-heart-failure-reccoedPw2km7vffR)
- [Acute Decompensated Heart Failure National Registry (ADHERE) Algorithm](https://www.pathway.md/calculators/acute-decompensated-heart-failure-national-registry-adhere-algorithm-recoST2VfUSoi9xU7)
- [Assessment of diastolic dysfunction severity (with LV structural pathology)](https://www.pathway.md/calculators/assessment-of-diastolic-dysfunction-severity-with-lv-structural-pathology-recQmg5VTtYBm8Jrf)
- [Revised Cardiac Risk Index for perioperative risks (RCRI)](https://www.pathway.md/calculators/revised-cardiac-risk-index-for-perioperative-risks-rcri-recRVQPCEDZg3gOl7)
- [Killip classification for heart failure](https://www.pathway.md/calculators/killip-classification-for-heart-failure-recwix2r11esPA70H)

---

**Document Status**: Complete with 71 PubMed reference links extracted from the source material  
**Last Updated**: January 2025  
**Source Verification**: References validated against https://www.pathway.md/diseases/heart-failure-rectslm30dGoeF3RH